BioSpace News Archive

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2024 financial results.

Fate Therapeutics, Inc. will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results.

ZygoFix Ltd. a portfolio company of The Trendlines Group Ltd. (“Trendlines”) announced that it received regulatory clearance from the United States Food and Drug Administration (FDA clearance) for its zLOCK Lumbar Facet Fixation System.

Regulus Therapeutics Inc. today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months.

HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow.

Ratio Therapeutics Inc. today announced the appointment of Marc Becker as the company’s Chief Financial Officer and Chief Operating Officer.

GE HealthCare, a leader in precision care innovation, will host an investor day on Thursday, November 21, 2024, in New York, NY.

Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-March 2024.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the Swedish Medical Products Agency has approved the initiation of a Phase I clinical study of the drug candidate IRL757.